FLIC - Functional Ligands for Imaging in Cancer

磁共振成像（MRI）和正电子发射断层扫描（PET）是两种基本的成像方法，其在癌症研究中的临床应用已经很好地建立。临床仪器的最新进展已经导致具有改进的分辨率和灵敏度的设备。然而，目前用于MRI和PET的造影剂或成像剂对于现在正在部署的21世纪仪器来说并不那么有效。设计，合成和验证改进的，新的功能成像探针是迫切需要的。为了开发这样的癌症探针，需要一个多学科团队，在合成化学和放射化学，临床前和临床成像科学以及癌症药物开发方面具有专业知识，并与癌症生物学的需求和愿望保持一致。目前，联合王国没有一个单一的集团能够提供这一系列的专门知识，因此，要在这一重要领域取得进展，必须建立一个多中心的合作集团。拟议的FLIC平台赠款将建立一个在化学，癌症成像和药物开发方面具有优势的合作团队，并在此过程中创建一个化学-生命科学接口，以满足个性化医疗的关键需求，生产新的化学实体，为医疗保健提供者提供真正的实用性，并适合商业开发。

Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) are two essential imaging methods whose clinical application in cancer research is well established. Recent advances in clinical instrumentation have resulted in equipment with improved resolution and sensitivity. However, current contrast or imaging agents for use in MRI and PET are not as effective for the 21st century instrumentation now being deployed. The design, synthesis and validation of improved, new functional imaging probes is urgently needed. To develop such probes for cancer a multidisciplinary team is required with expertise in synthetic chemistry and radiochemistry, pre-clinical and clinical imaging sciences, and cancer drug development, working in harmony with the needs and aspirations of cancer biology. No single grouping in the UK can currently offer this range of expertise, and therefore to make progress in this important area the formation of a multi-centre collaborative grouping is essential. The proposed FLIC platform grant will establish a collaborative team with strengths in chemistry, cancer imaging and drug development, and in so doing create a chemistry-life science interface that will address a key need in personalised medicine, producing new chemical entities with genuine utility for healthcare providers and amenable to commercial exploitation.